ArticleClinical kidney journal2025

First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.

Moritz Schanz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.